Physician profile
Sumona Saha
NPI 1720204605
$10,717.24
in general payments reported to CMS, 2019-2025
9 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $2,100 · 2022: $150 · 2023: $296 · 2024: $5,391 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,635 · Food and Beverage: $1,066 · Travel and Lodging: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,635.00 |
| Food and Beverage | $1,066.10 |
| Travel and Lodging | $616.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,727.94 | 2024 | |
| Janssen Biotech, INC. | $2,368.95 | 2025 | Tremfya |
| Abbvie INC. | $1,950.00 | 2021 | |
| Celgene Corporation | $662.94 | 2024 | |
| Biogen, INC. | $600.00 | 2019-2025 | Tysabri |
| Cook Medical LLC | $167.57 | 2023-2025 | Echotip Insight, Hemospray |
| Takeda Pharmaceuticals U.S.A., INC. | $150.00 | 2022 | |
| Aimmune Therapeutics, INC. | $89.84 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumona Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.